UBS Group Lowers Owens & Minor (NYSE:OMI) Price Target to $13.00

Owens & Minor (NYSE:OMI - Get Free Report) had its price objective reduced by equities researchers at UBS Group from $25.00 to $13.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective points to a potential upside of 74.61% from the stock's previous close.

A number of other equities research analysts have also recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Owens & Minor from $15.00 to $14.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. Barclays dropped their price objective on shares of Owens & Minor from $18.00 to $14.00 and set an "equal weight" rating for the company in a report on Tuesday, November 5th. Finally, Citigroup dropped their price target on Owens & Minor from $21.00 to $18.50 and set a "buy" rating for the company in a report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $16.79.

Owens & Minor Price Performance

Shares of OMI traded down $0.30 during mid-day trading on Thursday, reaching $7.45. The company had a trading volume of 1,560,012 shares, compared to its average volume of 1,028,394. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.45. The company's 50-day moving average is $12.80 and its 200-day moving average is $13.82. Owens & Minor has a twelve month low of $7.41 and a twelve month high of $28.35. The company has a market capitalization of $574.08 million, a P/E ratio of -11.45, a P/E/G ratio of 0.25 and a beta of 0.48.

Insider Activity

In related news, CFO Jonathan A. Leon sold 5,282 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $11.82, for a total value of $62,433.24. Following the transaction, the chief financial officer now directly owns 130,822 shares in the company, valued at $1,546,316.04. This represents a 3.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 3.59% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Coliseum Capital Management LLC lifted its stake in Owens & Minor by 31.3% in the fourth quarter. Coliseum Capital Management LLC now owns 4,785,964 shares of the company's stock valued at $62,553,000 after buying an additional 1,141,483 shares during the period. Freestone Grove Partners LP acquired a new position in shares of Owens & Minor during the 4th quarter worth about $5,125,000. Foundry Partners LLC acquired a new position in shares of Owens & Minor during the 3rd quarter worth about $5,238,000. Charles Schwab Investment Management Inc. grew its position in shares of Owens & Minor by 13.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,305,043 shares of the company's stock worth $30,127,000 after buying an additional 276,807 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Owens & Minor by 77.0% during the 4th quarter. Deutsche Bank AG now owns 495,111 shares of the company's stock worth $6,471,000 after buying an additional 215,455 shares during the period. Institutional investors and hedge funds own 98.04% of the company's stock.

About Owens & Minor

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.